Change in α1 HDL concentration predicts progression in coronary artery stenosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 23, Issue 5, 2003, Pages 847-852

  Asztalos, Bela F ^a   Batista, Marcelo ^a   Horvath, Katalin V ^a   Cox, Caitlin E ^a   Dallal, Gerard E ^a   Morse, Josh S ^b   Brown, Greg B ^b   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Coronary heart disease; Coronary stenosis; HDL subpopulations; Niacin; Statin

Indexed keywords

ALPHA TOCOPHEROL; ALPHA1 HIGH DENSITY LIPOPROTEIN; ANTIOXIDANT; APOLIPOPROTEIN A1; ASCORBIC ACID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LIPOPROTEIN; NICOTINIC ACID; SELENIUM; SIMVASTATIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN A2; VITAMIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID COMPOSITION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; AGAR GEL ELECTROPHORESIS; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; PARTICLE SIZE; RADIOGRAPHY; TREATMENT OUTCOME;

AGED; ANTIOXIDANTS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; CORONARY STENOSIS; DISEASE PROGRESSION; ELECTROPHORESIS, AGAR GEL; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NIACIN; PARTICLE SIZE; SIMVASTATIN; TREATMENT OUTCOME; VITAMINS;

EID: 0038300497     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000066133.32063.BB     Document Type: Article

References (27)

1. Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischemic heart disease. Lancet. 1975;1:16-19.
2. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR, Bangdiwala S, Tyroler HA. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8-15.
3. Krauss RM. Triglycerides and atherogenic lipoproteins: rationale for lipid management. Am J Med. 1998;105:48S-62S.
4. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997;17:107-113.
5. von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high-density lipoprotein cholesterol. Curr Opin Lipidol. 2000;11: 627-637.
6. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle-aged adults during the era of hypertensive therapy: Framingham Offspring Study. Am J Med. 1991;90:11-16.
7. Mowri HO, Patsch W, Smith LC, Gotto AM, Patsch JR. Different reactivities of high-density lipoprotein2 subtractions with hepatic lipase. J Lipid Res. 1992;33:1269-1279.
8. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein. Biochemistry. 1988;27: 25-29.
9. Miida T, Kawano M, Fielding CJ, Fielding PE. Regulation of the concentration of preβ high-density lipoprotein in normal plasma by cell membranes and lecithin-cholesterol acyltransferase activity. Biochemistry. 1992;31:11112-11117.
10. von Eckardstein A, Huang Y, Assmann G. Physiological role and clinical relevance of high density lipoprotein subclasses. Curr Opin Lipidol. 1994;5:404-416.
11. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol. 2000;20:2670-2676.
12. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res. 2002;43:1701-1707.
13. Cheung MC, Brown BG, Wolf AC, Albers JJ. Altered particle size distribution of apolipoprotein A-I containing lipoproteins in subjects with coronary heart disease. J Lipid Res. 1991;32:383-394.
14. Fruchart JC, Ailhaud G. Apolipoprotein A-containing lipoprotein particles: physiological role, quantification, and clinical significance. Clin Chem. 1992;38:793-797.
15. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ, Schaefer EJ. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis. 2002;164:361-369.
16. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral artery disease. JAMA. 2000;284:1263-1270.
17. Atmeh RF, Shepherd J, Packard CJ. Subpopulations of apolipoprotein A-I in human high density lipoproteins: their metabolic properties and response to drug therapy. Biochim Biophys Acta. 1983;751:175-188.
18. Asztalos BF, Sloop CH, Wong L, Roheim PS. Two-dimensional electrophoresis of plasma lipoproteins: recognition of new apo A-I-containing subpopulations. Biochim Biophys Acta. 1993;1169:291-300.
19. Asztalos BF, Lefevre M, Foster TA, Tulley R, Widhauser M, Wong L, Roheim PS. Normolipidemic subjects with low HDL cholesterol levels have altered HDL subpopulations. Arterioscler Thromb Vasc Biol. 1997; 17:1885-1893.
20. Brown GB, Zhao XQ, Chait A, Frohlich J, Cheung M, Heise N, Dowdy A, DeAngelis D, Fisher LD, Albers J. Lipid altering or antioxidant vitamins for patients with coronary disease and very low HDL cholesterol? The HDL-Atherosclerosis Treatment Study design. Can J Cardiol. 1998;14(suppl A):6A-13A.
21. Brown GB, Zhao XQ, Chait A, Fisher LD, Cheung M, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovich P, Frohlich J, Albers JJ. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
22. Cheung MC, Zhao XQ, Chait A, Albers JJ, Brown GB. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol. 2001;21:1320-1326.
23. Contois JH, McNamara JR, Lammi-Keefe CJ, Wilson PWF, Massov T, Schaefer EJ. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidometric assay: results from the Framingham Offspring Study. Clin Chem. 1996;42: 515-523.
24. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada N, Nakamura H, Campos E, Havel RJ. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apoB-100 and anti apoA-I immunoaffinity mixed gels. Clin Chim Acta. 1993;223:53-71.
25. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesterol ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol. 2000;20:189-197.
26. Brown GB, Cheung MC, Lee AC, Zhao XQ, Chait A. Antioxidant vitamins and lipid therapy. Arterioscler Thromb Vasc Biol. 2002;22: 1535-1546.
27. Sweetnam PM, Bolton CH, Yarnel IW, Bainton D, Baker IA, Elwood PC, Miller NE. Associations of HDL2 and HDL3 cholesterol subfractions with the development of ischemic heart disease in British men. Circulation. 1994;90:769-774.